Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment

Overview:

Acute Respiratory Distress Syndrome is an acute lung dysfunction, which occurs as a result of injury or illness. It is known as adult respiratory distress syndrome, it may also affect children. In this condition small air sacs (alveoli) in lungs are accumulated with fluid which makes difficulty in passing of oxygen into blood stream. Symptoms of acute respiratory distress syndrome includes difficulty in breathing, rapid breathing, hyper ventilation. ARDS can be developed into deep infection which causes pneumonia, trauma.

ARDS can be diagnosed by blood tests, chest x-rays and others. Treatment for the ARDS are mechanical ventilation, supplemental oxygen, fluid management and a technique called positive end expiratory pressure (PEEP) to help push the fluid out of air sacs, extracorporeal membrane oxygenation, human mesenchymal stem cells.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/acute-respiratory-distress-syndrome-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:

By Drugs, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

1. Interferon Beta-1a
2. Imatinib
3. Sivelestat
4. L-Citrulline
5. Poractantalfa
6. Ganciclovir
7. Others

By Route of Administration, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

1. Oral
2. Parenteral

By Trial Phase, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

1. Preclinical Trials
2. Phase 1
3. Phase 2
4. Phase 3
5. Phase 4

By Company, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

1. AltorBioScience
2. Genentech, Inc.
3. Faron Pharmaceuticals Ltd.
4. AltorBioScience
5. Suntory Pharmaceutical
6. Eli Lilly and Company
7. Asklepion Pharmaceuticals, LLC
8. BioMarck Pharmaceuticals, Ltd.
9. Others

Space Analysis:

1. In January 2016, Chiesi Farmaceutici S.p.A initiated phase II clinical trials of its CHF 5633 in neonatal respiratory distress syndrome.
2. In August 2017, BioMarck Pharmaceuticals initiated Phase-II clinical trials in Adult respiratory distress syndrome in USA (Inhalation)

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/acute-respiratory-distress-syndrome-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

Report Description:

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Respiratory Distress Syndrome treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Respiratory Distress Syndrome disease pipeline drugs development. This report studies the dynamics of the Acute Respiratory Distress Syndrome Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Respiratory Distress Syndrome disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/acute-respiratory-distress-syndrome-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Key Features of the Report:

1. Provides the information related to universities and research institutes working in the therapeutics development
2. Report comprehensively covers the all active and discontinued studies
3. Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
4. Presents the prominent targets for drug development in each stage of clinical trial
5. Provides the in-depth analysis on the each drug candidates in the clinical trial phases
6.  

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/acute-respiratory-distress-syndrome-disease-pipeline-drugs-assessment/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com